<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776606</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-CL019</org_study_id>
    <nct_id>NCT01776606</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines</brief_title>
  <acronym>RADIANT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of botulinum toxin type A compared to
      placebo control for the treatment of moderate to severe crow's feet lines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint based upon the investigator global assessment and patient assessment of severity of lateral canthal lines</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 2 point or greater improvement from baseline using the Investigator Global Assessment</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 1 point or greater improvement from baseline using the Investigator Global Assessment</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a 2 point or greater improvement from baseline using the Patient Severity Assessment</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Skin Aging</condition>
  <arm_group>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose A: Botulinum toxin type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose B: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines</description>
    <arm_group_label>Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, Dose B; dose applied to the lateral canthal lines</description>
    <arm_group_label>Dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe crow's feet lines

          -  Female or male, 18 to 65 years of age and in good general health

          -  Women of childbearing potential (WOCBP) must agree to use an effective method of birth
             control during the course of the study

        Exclusion Criteria:

          -  Any neurological condition that may place the subject at increased risk with exposure
             to botulinum toxin type A

          -  Muscle weakness or paralysis, particularly in the area receiving study treatment

          -  Active skin disease or irritation at the treatment area

          -  Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated
             by manually spreading the skin apart

          -  Treatment with botulinum toxin type A for crow's feet lines in the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <disposition_first_submitted>August 9, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2013</disposition_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

